New Study Confirms Long-Term Effectiveness of Tirzepatide in Sustained Weight Loss Over Three Years
A recent study has revealed that the drug Tirzepatide—commercially known as Mounjaro and Zepbound—significantly contributes to sustained weight loss when administered weekly for at least three years in adults who are overweight or obese and not diagnosed with diabetes.
The preliminary results were published on the European Association for the Study of Obesity (EASO) website on April 11, 2025, with full findings to be presented at the association’s upcoming conference scheduled for May 11–14 in Málaga, Spain.
The study was led by Dr. Luca Busetto of the University of Padua in Italy, in collaboration with Eli Lilly, the pharmaceutical company that manufactures Tirzepatide. Dr. Busetto explained that individuals’ responses to the medication varied, with the most responsive groups being women and non-diabetic adults suffering from overweight or obesity.
Promising Results Across Three Participant Groups
Participants who consistently used the medication over the three-year period were divided into three groups based on their level of weight loss:
- Group One: Lost approximately 10% of their original weight and were the fastest to reach a weight plateau.
- Group Two: Achieved a 20% weight loss before stabilizing.
- Group Three: Showed the highest response, losing up to 30% of their initial weight, although they took longer to reach the plateau. This group primarily consisted of women and non-diabetic adults.
Most participants reached a stable weight within 6 to 12 months of starting the treatment and successfully maintained their new weight. These findings reinforce the long-term efficacy of Tirzepatide when used continuously for weight management.
GLP-1 Agonists: A New Era in Weight Loss Treatment
Tirzepatide belongs to a class of drugs known as GLP-1 receptor agonists, which mimic the natural hormone GLP-1. These medications help lower blood sugar levels and support weight loss, especially in individuals with type 2 diabetes or obesity.
Notable GLP-1 agonists include:
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Liraglutide (Victoza, Saxenda)
- Dulaglutide (Trulicity)
- Exenatide (Byetta, Bydureon)
- Lixisenatide (Adlyxin)
Additionally, there is a newer class of dual-action drugs targeting both GLP-1 and GIP receptors, with Tirzepatide being a prominent example.
These medications are usually administered via subcutaneous injection, typically in areas such as the abdomen, thighs, upper arms, or buttocks.
Side Effects and Safety Profile
The study did not identify any new health risks associated with Tirzepatide. However, it reaffirmed the presence of some commonly observed side effects, such as nausea, diarrhea, or constipation—most of which tend to diminish over time with continued use.
Conclusion
This study supports the use of Tirzepatide as an effective long-term solution for weight loss and weight maintenance, particularly among non-diabetic individuals. It may serve as a valuable addition to obesity treatment plans alongside lifestyle and dietary changes.
